On this page
What belongs in the first-year general investigational plan for an IND?
Under 312.23(a)(3)(iv), describe the rationale, indications, general evaluation approach, kinds of trials planned for the following year, estimated patients to receive the drug and particularly severe or serious anticipated risks. Tie those elements to the actual evidence and study plans. Identify undeveloped portions honestly; the general plan neither replaces the detailed protocols nor authorizes an otherwise unready investigation.
Before you begin
Initial IND general investigational plan under 21 CFR 312.23(a)(3)(iv). It is distinct from detailed protocols, the investigator brochure and the subsequent annual-report update at 1.13.9.
What you will prepare: A concise first-year investigation plan that agrees with the actual development evidence and explicitly identifies undeveloped portions.
Define the first-year question
Begin with the rationale for studying the product, the indication and general evaluation approach. Section 312.23(a)(3)(iv) addresses the following year, not an invented complete development program. Identify the planned types of clinical trials, estimated number of patients to receive the drug and particularly serious anticipated risks. Where plans are not developed for the entire year, the provision allows the sponsor to say so; uncertainty should not be hidden behind fictional studies.
Connect the narrative to actual planned studies
| Plan element | Source to inspect | Writing output |
|---|---|---|
| Rationale and indication | Scientific strategy and supporting evidence | The question and why this investigation is justified |
| Study sequence | Actual protocol concepts and dependencies | What is planned first and what later decisions depend on |
| Estimated exposure | Recruitment and cohort assumptions | A transparent estimate with its assumptions |
| Material risks | Assessed toxicology and prior human evidence | The specific concerns informing the plan |
Use study identifiers where available and identify concepts as concepts. Keep the plan aligned with submitted protocols without repeating their full operational detail.
Explain uncertainty and safeguards through the right owners
Identify serious anticipated risks supported by the evidence and reconcile their treatment with the brochure and protocol. Do not invent dose limits, stopping rules or monitoring thresholds in a general writing guide. Distinguish known findings from uncertainties requiring further work. The plan does not replace protocol amendments, safety reporting or other applicable obligations when the program changes.
Fictional example: an undecided second study
The team has a defined first study but a second study depends on emerging exposure and safety findings. Describe the known first-year work and the decision dependency, explicitly stating where the later plan is not developed. Do not fabricate a protocol number, patient count or start date. If the task is instead an IND annual update, describe the coming year and route it through the appropriate annual-report task rather than labeling it a new initial plan.
Write the six elements as one coherent investigation plan
Start with the scientific question and explain how the proposed first-year work will address it. A list of study names is not enough if the reader cannot understand their sequence, assumptions or relationship to the evidence. Use this drafting map to cover the six elements in 312.23(a)(3)(iv).
| Element | Writing task | Reconciliation check |
|---|---|---|
| Rationale | Explain why the drug or research study is justified | Does the cited evidence support the actual formulation and proposed investigation? |
| Indication | State the condition or use being studied | Does it agree with the study population rather than an aspirational future label? |
| General approach | Explain the questions and overall evaluation strategy | Do planned studies address those questions? |
| First-year trial types | Identify defined studies and conditional later work | Are undeveloped portions explicitly described as undeveloped? |
| Estimated drug recipients | Show the estimate and assumptions for the planned studies | Are screening, placebo-only participants and repeated participation distinguished? |
| Particularly severe or serious risks | Summarize assessed animal and prior-human concerns, including related-drug evidence | Are risk statements consistent with the brochure and protocol controls? |
Add a short dependency record where the study sequence needs explanation: proposed next activity, information it depends on, responsible scientific decision and current planning status. This is a planning aid, not a replacement for the actual protocol, required review or IND procedures. Do not invent a study identifier, start date or numerical decision threshold merely to fill a blank cell.
Fictional counting exercise: an actual defined study plan estimates 48 randomized participants, of whom 32 are assigned investigational drug and 16 placebo. The drug-recipient estimate is 32 under those assumptions, not 48, and the screening target is a separate number. If a later crossover will expose placebo participants to drug, reassess the estimate using that design. Across studies, disclose the counting basis and any expected overlap rather than silently equating exposure episodes with unique people.
Suppose a second study will be designed only after the first study's exposure and safety assessment. Describe the dependency and the portion of the coming year that remains undeveloped. Do not add several mutually exclusive study concepts into a single apparently committed patient total. If useful, present explicitly labeled scenarios with their assumptions, making clear which work is defined and which is contingent. The provision permits the sponsor to state that plans are not developed for the entire year.
For anticipated serious risks, identify the finding and its relevance to the proposed investigation, then point to the assessed controls in the appropriate documents. Distinguish a finding with this product from a related-drug concern. The writing task is to communicate the scientific decision and uncertainty, not to invent a dose ceiling, monitoring frequency or stopping rule.
Reconcile the plan with the investigator brochure and the actual submitted protocols under 312.23(a)(6). Subsequent protocol submissions follow their applicable IND process. The annual-report guide addresses the later coming-year replacement plan under 312.33(c); copying an unchanged initial narrative is insufficient if the actual program and evidence have changed.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Must the entire first year be fully planned before writing the general investigational plan?
The provision expressly contemplates plans that are not developed for the entire year and says the sponsor should indicate that. Describe the defined work, current assumptions and dependencies honestly. Do not fabricate studies or patient numbers to make an uncertain development sequence appear fully determined.
Should the estimated patient number include everyone screened or assigned placebo?
Section 312.23(a)(3)(iv) asks for the estimated patients to be given the drug in those studies. Reconcile the estimate with the actual design, separating screening and placebo-only participation. Explain crossover exposure, overlap and other assumptions where relevant instead of using the largest recruitment number without qualification.
Can the general investigational plan replace the study protocols or investigator brochure?
No. The overall first-year plan, study protocols and investigator brochure serve different purposes and have separate IND provisions. Keep their scientific rationale, risk statements and study assumptions aligned. A brief description of a future study in the plan does not replace the applicable protocol submission and other conditions for starting it.
How is the initial plan different from the annual-report investigational plan?
The initial plan describes the following year under 312.23(a)(3)(iv). Section 312.33(c) calls for a coming-year plan replacing the one submitted a year earlier, with the same specified information. Update it to reflect actual results, changed assumptions and current proposed work rather than merely changing the date.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR Part 312: IND content and sponsor responsibilities ↗312.23(a)(3)(iv), 312.23(a)(5), 312.33 and 312.55. Full Part 312 text current through September 18, 2026; checked September 22. Individual 312.23 URL was blocked; full part was inspected.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.20. A heading identifies placement, not mandatory applicability.